| P4 Physical Therapy - Athens, Llc | |
|
209 Fitness Way Ste D, Athens, AL 35611-2452 | |
| (205) 478-4418 | |
| (205) 999-4622 |
| Full Name | P4 Physical Therapy - Athens, Llc |
|---|---|
| Type | Facility |
| Speciality | Physical Therapist |
| Location | 209 Fitness Way Ste D, Athens, Alabama |
| Accepts Medicare Assignments | Medicare enrolled and accepts medicare insurance. Providers at this facility may prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295350783 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 225100000X | Physical Therapist | (* (Not Available)) | Primary |
| Provider Name | Donald Lea Smith |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1205979648 PECOS PAC ID: 0749305282 Enrollment ID: I20100921000408 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Tracy Causey |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1740224088 PECOS PAC ID: 0446224000 Enrollment ID: I20110426000102 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Ashley Walker |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1598915357 PECOS PAC ID: 8426280454 Enrollment ID: I20140407000502 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | John William Holley |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1720402746 PECOS PAC ID: 6406074657 Enrollment ID: I20140829000625 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Mason Anthony Montney |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1912356452 PECOS PAC ID: 1254623515 Enrollment ID: I20160706001531 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Bradley Kenneth Moorer |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1184279317 PECOS PAC ID: 3870824675 Enrollment ID: I20191009001230 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Cole Brennen White |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1952902249 PECOS PAC ID: 3779994918 Enrollment ID: I20201119002099 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Elizabeth Parker Dixon |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1609440973 PECOS PAC ID: 9931599628 Enrollment ID: I20211213001558 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Provider Name | Carson Wade Mcgregory |
|---|---|
| Provider Type | Practitioner - Physical Therapist In Private Practice |
| Provider Identifiers | NPI Number: 1760147466 PECOS PAC ID: 2668866484 Enrollment ID: I20220221002100 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
| Mailing Address | Practice Location Address |
|---|---|
| P4 Physical Therapy - Athens, Llc 8059 Mitchell Ln, Vestavia Hills, AL 35216-6821 Ph: (205) 229-8376 | P4 Physical Therapy - Athens, Llc 209 Fitness Way Ste D, Athens, AL 35611-2452 Ph: (205) 478-4418 |
News Archive
A new protein, called aquaporin-4, is making waves and found to play a key role in brain inflammation, or encephalitis. This discovery is important as the first to identify a role for this protein in inflammation, opening doors for the development of new drugs that treat brain inflammation and other conditions at the cellular level rather than just treating the symptoms.
Chemotherapeutic drugs excel at fighting cancer, but they're not so efficient at getting where they need to go.
Giving early-stage pancreatic cancer patients a CD40 immune-stimulating drug helped jumpstart a T cell attack to the notoriously stubborn tumor microenvironment before surgery and other treatments, according to a new study from researchers in the Abramson Cancer Center (ACC) at the University of Pennsylvania.
Helsinn, the Swiss Group focused on building quality cancer care, announces today that on 27th May 2015, the European Commission (EC) approved Akynzeo® (netupitant-palonosetron) for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cisplatin-based cancer chemotherapy and moderately emetogenic cancer chemotherapy in the European Union.
› Verified 1 days ago
Helen J Block, PT, DPT Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 209 Fitness Way Ste D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
Benchmark Pt - Athens Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 936 Us Highway 72 E Ste 170, Athens, AL 35611 Phone: 256-230-1252 Fax: 256-230-1256 | |
Joseph J Kribs, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 209 Fitness Way Ste D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
Mrs. Farrah Renee Haley, PT Physical Therapist Medicare: Medicare Enrolled Practice Location: 209 Fitness Way, Suite D, Athens, AL 35611 Phone: 256-233-9148 Fax: 256-233-9164 | |
P4 Physical Therapy Limited Partnership Physical Therapist Medicare: Not Enrolled in Medicare Practice Location: 15641 E Limestone Rd, Athens, AL 35613 Phone: 256-937-1360 | |
Mrs. Abreia R Thomas, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 1260 Us Highway 72 E, Suite A, Athens, AL 35611 Phone: 256-233-4486 Fax: 256-230-6908 | |
Sarah Lancaster, PT, DPT Physical Therapist Medicare: Accepting Medicare Assignments Practice Location: 22454 Us Highway 72 # 210, Athens, AL 35613 Phone: 256-233-4486 |